Anil V. Pathare, Shoaib Al Zadjali, Rhea Misquith, Salam S. Alkindi, Vinodh Panjwani, Claudine Lapoumeroulie, Sahaya Pravin, Andras Paldi, Rajagopal Krishnamoorthy
Human Biology 84 (1), 67-77, (1 February 2012) https://doi.org/10.3378/027.084.0103
KEYWORDS: PHARMACOGENETICS, CYP2C9, CYP4F2, VKORC1, WARFARIN, OMANI
This is the first study to evaluate the spectrum and prevalence of dose-predictive genetic polymorphisms of the CYP2C9, CYP4F2 and VKORC1 loci together, in a geographically defined, ethnically admixed healthy adult Omani population sharing common lifestyle/environmental factors. Since the present-day Omani population is the result of an admixture of Caucasian, African and Asian ancestries, we compared the pharmacogenetic profile of these three loci in this population. Interestingly, the Omani pharmacogenetic profile, in terms of allele and genotype distribution, has values that are intermediate between Caucasians and African Americans, the African admixture further substantiated by the presence of the CYP2C9*8 allele. However, limitations and usefulness of such comparisons warrant caution, as the data from pharmacogenetic literature do not always represent bona fide population categories. Furthermore, definition of study population based on microgeographical scale would be more appropriate in pharmacogenetic research rather than the flawed racial, ethnic, or social categorizations since pharmacogenetic variation is clinal, and genetic influences will be further altered by lifestyle and environmental factors.